|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Product revenue, net | |||||
| Sale of COPIKTRA license and related assets | |||||
| Total revenue | |||||
| Operating expenses: | |||||
| Cost of sales - product | |||||
| Cost of sales - intangible amortization | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other expense | |||||
| Interest income | |||||
| Interest expense | |||||
| Loss on debt extinguishment | |||||
| Change in fair value of preferred stock tranche liability | |||||
| Change in fair value of warrant liability | |||||
| Change in fair value of Notes | |||||
| Net loss before taxes | |||||
| Income tax expense | |||||
| Net loss | |||||
| Unrealized gain (loss) on available-for-sale securities | |||||
| Change in fair value of Notes attributable to instrument specific credit risk | |||||
| Comprehensive loss | |||||
| Net loss per share-basic | |||||
| Net loss per share-diluted | |||||
| Weighted average common shares outstanding used in computing net loss per share - basic | |||||
| Weighted average common shares outstanding used in computing net loss per share - diluted | |||||
Loading...
